P53 expression is significantly correlated with high risk of malignancy and epithelioid differentiation in GISTs. An immunohistochemical study of 104 cases

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Pauser, Ursula ^a   Schmedt auf der Günne, Nina ^b,c   Klöppel, Günter ^b   Merz, Hartmut ^a   Feller, Alfred C ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c ALBERTINEN KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLIN D1; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; STEM CELL FACTOR; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CORRELATION ANALYSIS; DISEASE MARKER; EPITHELIOID CELL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; METASTASIS; MITOSIS RATE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; CYTOLOGY; EPITHELIUM CELL; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; EPITHELIAL CELLS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49749140039     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-204     Document Type: Article

References (45)

1. Hornick JL Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007, 38:679-687. 10.1016/j.humpath.2007.03.001 17437861
2. Steigen SE Eide TJ Wasag B Lasota J Miettinen M: Mutations in gastrointestinal stromal tumors - a population-based study from Northern Norway. APMIS 2007, 115:289-298. 10.1111/j.1600-0463.2007.apm_587.x 17504295
3. Lasota J Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008. 18312355
4. Hirota S Isozaki K Moriyama Y Hashimoto K Nishida T Ishiguro S Kawano K Hanada M Kurata A Takeda M Muhammad TG Matsuzawa Y Kanakura Y Shinomura Y Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580. 10.1126/ science.279.5350.577 9438854
5. Hirota S Nishida T Isozaki K Taniguchi M Nakamura J Okazaki T Kitamura Y: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001, 193:505-510. 10.1002/ 1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E 11276010
6. Taniguchi M Nishida T Hirota S Isozaki K Ito T Nomura T Matsuda H Kitamura Y: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59:4297-4300. 10485475
7. Heinrich MC Corless CL Duensing A McGreevey L Chen CJ Joseph N Singer S Griffith DJ Haley A Town A Demetri GD Fletcher CD Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710. 10.1126/science.1079666 12522257
8. Weiss SW Goldblum JR: Soft tissue tumors. St. Louis: Mosby, Inc Fourth 2001
9. Reichardt P Hohenberger P: Gastrointestinale Stromatumoren (GIST). Bremen: Uni-MED 2006
10. Fletcher CD Berman JJ Corless C Gorstein F Lasota J Longley BJ Miettinen M O'Leary TJ Remotti H Rubin BP Shmookler B Sobin LH Weiss SW: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-465. 10.1053/hupa.2002.123545 12094370
11. Miettinen M El Rifai W Sobin HL Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 2002, 33:478-483. 10.1053/hupa.2002.124123 12094372
12. Wardelmann E Neidt I Bierhoff E Speidel N Manegold C Fischer HP Pfeifer U Pietsch T: C-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002, 15:125-136. 10.1038/modpathol.3880504 11850541
13. Antonescu CR Viale A Sarran L Tschernyavsky SJ Gonen M Segal NH Maki RG Socci ND DeMatteo RP Besmer P: Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004, 10:3282-3290. 10.1158/1078-0432.CCR-03-0715 15161681
14. DeMatteo RP Gold JS Saran L Gonen M Liau KH Maki RG Singer S Besmer P Brennan MF Antonescu CR: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112:608-615. 10.1002/ cncr.23199 18076015
15. Gunawan B Bergmann F Hoer J Langer C Schumpelick V Becker H Fuzesi L: Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 2002, 33:316-321. 10.1053/hupa.2002.32216 11979372
16. Hillemanns M Pasold S Bottcher K Höfler H: Prognostic factors of gastrointestinal stromal tumors of the stomach. Verh Dtsch Ges Pathol 1998, 82:261-266. 10095444
17. Panizo-Santos A Sola I Vega F de Alava E Lozano MD Idoate MA Pardo-Mindan J: Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 2000, 8:133-144. 10.1177/106689690000800208 11493978
18. Al Bozom IA: P53 expression in gastrointestinal stromal tumors. Pathol Int 2001, 51:519-523. 10.1046/j.1440-1827.2001.01233.x 11472564
19. Cunningham RE Abbondanzo SL Chu WS Emory TS Sobin LH O'Leary TJ: Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol 2001, 9:19-23. 10.1097/00022744-200103000-00005 11277409
20. Sabah M Cummins R Leader M Kay E Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: Markers with potential prognostic implications Hum Pathol 2006 37 648 655 10.1016/ j.humpath.2006.01.023 16733203
21. Suster S Fisher C Moran CA: Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998, 22:863-872. 10.1097/00000478-199807000-00008 9669348
22. Noguchi T Sato T Takeno S Uchida Y Kashima K Yokoyama S Muller W: Biological analysis of gastrointestinal stromal tumors. Oncol Rep 2002, 9:1277-1282. 12375034
23. Steinert DM Oyarzo M Wang X Choi H Thall PF Medeiros LJ Raymond AK Benjamin RS Zhang W Trent JC: Expression of Bcl-2 in gastrointestinal stromal tumors: Correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006, 106:1617-1623. 10.1002/cncr.21781 16518826
24. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677. 10.1126/ science.274.5293.1672 8939849
25. Alao JP: The regulation of cyclin DR degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007, 6:24. 1851974 17407548 10.1186/1476-4598-6-24
26. Hunter T Pines J: Cyclins and cancer. Cell 1991, 66:1071-1074. 10.1016/ 0092-8674(91)90028-W 1833062
27. Michalides RJ: CeMl cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol 1999, 52:555-568. 500945 10645224
28. Gillett C Smith P Gregory W Richards M Millis R Peters G Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996, 69:92-99. 10.1002/ (SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q 8608989
29. Wong NA Young R Malcomson RD Nayar AG Jamieson LA Save VE Carey FA Brewster DH Han C Al Nafussi A: Prognostic indicators for gastrointestinal stromal tumours: A clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003, 43:118-126. 10.1046/j.1365-2559.2003.01665.x 12877726
30. Nakamura N Yamamoto H Yao T Oda Y Nishiyama K Imamura M Yamada T Nawata H Tsuneyoshi M: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005, 36:828-837. 10.1016/ j.humpath.2005.03.012 16084954
31. Miettinen M Lasota J: GastrPintestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83. 10.1053/ j.semdp.2006.09.001 17193820
32. Rudolph P Chiaravalli AM Pauser U Oschlies I Hillemanns M Gobbo M Marichal M Eusebi V Hofler H Capella C Kloppel G: Gastrointestinal mesenchymal tumors - immunophenotypic classification and survival analysis. Virchows Arch 2002, 441:238-248. 10.1007/s00428-002-0673-2 12242520
33. Hall PA Ray A Lemoine NR Midgley CA Krausz T: Lane DP p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991, 338:513. 10.1016/0140-6736(91)90586-E 1678471
34. Rubin BP Singer S Tsao C Duensing A Lux ML Ruiz R Hibbard MK Chen CJ Xiao S Tuveson DA Demetri GD Fletcher CD Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61:8118-8121. 11719439
35. Corless CL McGreevey L Haley A Town A Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160:1567-1572. 1850861 12000708
36. Lasota J Dansonka-Mieszkowska A Sobin LH Miettinen M: A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004, 84:874-883. 10.1038/ labinvest.3700122 15146165
37. Wardelmann E Buttner R Merkelbach-Bruse S Schildhaus HU: Mutation analysis of gastrointestinal stromal tumors: Increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007, 451:743-749. 10.1007/s00428-007-0473-9 17701051
38. Rudolph P Gloeckner K Parwaresch R Harms D Schmidt D: Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic study. Hum Pathol 1998, 29:791-800. 10.1016/S0046-8177(98)90447-6 9712419
39. Emory TS Sobin LH Lukes L Lee DH O'Leary TJ; Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol 1999, 23:82-87. 10.1097/00000478-199901000-00009 9888707
40. Feakins RM: The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005, 46:270-279. 10.1111/j.1365-2559.2005.02071.x 15720412
41. Sabah M Cummins R Leader M Kay E: Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: Markers with potential prognostic implications. Hum Pathol 2006, 37:648-655. 10.1016/ j.humpath.2006.01.023 16733203
42. Wardelmann E Hrychyk A Merkelbach-Bruse S Pauls K Goldstein J Hohenberger P Losen I Manegold C Buttner R Pietsch T: Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 2004, 6:197-204. 1867629 15269295
43. Lasota J Dansonka-Mieszkowska A Sobin LH Miettinen M: A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004, 84:874-883. 10.1038/ labinvest.3700122 15146165
44. Haller F Gunawan B von Heydebreck A Schwager S Schulten HJ Wolf-Salgo J Langer C Ramadori G Sultmann H Fuzesi L: Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 2005, 11:6589-6597. 10.1158/1078-0432.CCR-05-0329 16166437
45. Quintanilla-Martinez L Davies-Hill T Fend F Calzada-Wack J Sorbara L Campo E Jaffe ES Raffeld M: Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003, 101:3181-3187. 10.1182/ blood-2002-01-0263 12515730